Overall, these results suggest that inhibitors for HIF-1 and SP1 likely induce anticancer effects in cooperation by suppressing the activity of cancer-related cellular mechanisms (including the mechanisms underlying CSC regulation) while using MYC inhibitors as anticancer drugs requires some cautions. The gene discussed is HIF1A; the disease is cancer.